15th August 2024
The USPTO, China PTO and JPTO have granted the patent applications from 2017 valid by RCSI covering the ChemoGellTM platform. The EU-application is in its final stages or review.
These broad base patents describes the Composition-of-Matter and various formulations and applications essential to the oncology business that OncoLize develops.
OncoLize holds an exclusive, worldwide license to the technology covering all disease categories within Oncology. The company has full rights to establish its own patent portfolio based on the Licensed IP.